Fortress Biotech, Inc. (FBIO) Stock Score, Valuation & Financial Research
Fortress Biotech, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 63/100.
Quick answer for FBIO
Fortress Biotech, Inc. currently has a Wall Street Score of 63/100. The stored market price is $2.49. Its financial score is 12/100. Its valuation score is 100/100. These figures are a research snapshot, not a buy or sell recommendation.
What Fortress Biotech, Inc. does
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe co
FBIO financial snapshot
- Wall Street Score:
- 63/100
- Current price:
- $2.49
- Market capitalization:
- $82.7M
- Revenue:
- $68.5M
- Net income:
- $111.8M
- Free cash flow:
- $-65.8M
- Cash:
- $196.6M
- Total debt:
- $64.8M
- EPS:
- 3.27
- P/E ratio:
- 0.8x
- Financial score:
- 12/100
- Valuation score:
- 100/100
- Revenue score:
- 51/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-65.8M, showing cash burn in the current stored period.
- The balance sheet shows $196.6M of cash versus $64.8M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research FBIO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.